MX2020013601A - Receptores de las celulas t especificos de cancer. - Google Patents
Receptores de las celulas t especificos de cancer.Info
- Publication number
- MX2020013601A MX2020013601A MX2020013601A MX2020013601A MX2020013601A MX 2020013601 A MX2020013601 A MX 2020013601A MX 2020013601 A MX2020013601 A MX 2020013601A MX 2020013601 A MX2020013601 A MX 2020013601A MX 2020013601 A MX2020013601 A MX 2020013601A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- bispecific
- vaccine
- pharmaceutical composition
- vector
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- 108091008874 T cell receptors Proteins 0.000 title 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title 1
- 230000001093 anti-cancer Effects 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 230000002163 immunogen Effects 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 229960005486 vaccine Drugs 0.000 abstract 4
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/001149—Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente descripción se refiere a un nuevo péptido anti-cáncer; un vector que codifica el mismo; una composición farmacéutica o agente inmunogénico o biespecífico o vacuna que comprende dicho péptido anti-cáncer; uso de dicho péptido anti-cáncer, vector, composición farmacéutica, agente inmunogénico, biespecífico o vacuna para tratar el cáncer; un método para tratar el cáncer usando dicho péptido anti-cáncer, vector, composición farmacéutica, agente inmunogénico, biespecífico o vacuna; y una combinación terapéutica para el tratamiento del cáncer que comprende dicho péptido anti-cáncer, vector, composición farmacéutica, agente inmunogénico, biespecífico o vacuna.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1810358.0A GB201810358D0 (en) | 2018-06-25 | 2018-06-25 | Cancer-specific t-cell receptors |
| PCT/GB2019/051785 WO2020002899A1 (en) | 2018-06-25 | 2019-06-25 | Cancer-specific t-cell receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013601A true MX2020013601A (es) | 2021-03-09 |
Family
ID=63042790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013601A MX2020013601A (es) | 2018-06-25 | 2019-06-25 | Receptores de las celulas t especificos de cancer. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12053513B2 (es) |
| EP (1) | EP3810175A1 (es) |
| JP (1) | JP2021529181A (es) |
| KR (1) | KR20210023822A (es) |
| CN (1) | CN112292392A (es) |
| AU (1) | AU2019295371A1 (es) |
| BR (1) | BR112020023182A2 (es) |
| CA (1) | CA3099677A1 (es) |
| EA (1) | EA202092861A1 (es) |
| GB (1) | GB201810358D0 (es) |
| IL (1) | IL279621A (es) |
| MX (1) | MX2020013601A (es) |
| SG (1) | SG11202010976PA (es) |
| WO (1) | WO2020002899A1 (es) |
| ZA (1) | ZA202006675B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220233662A1 (en) * | 2020-12-30 | 2022-07-28 | University College Cardiff Consultants Ltd. | Novel peptide |
| WO2023118820A1 (en) * | 2021-12-21 | 2023-06-29 | Continuum Life Sciences Limited | Cancer specific t-cell receptors |
| GB202211194D0 (en) | 2022-08-01 | 2022-09-14 | Univ College Cardiff Consultants Ltd | Novel TCRs |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0814140A2 (pt) * | 2007-07-27 | 2017-03-28 | Immatics Biotechnologies Gmbh | composição de peptídeos associados a tumor e vacina anticâncer relacionada |
| US9808504B2 (en) * | 2009-09-22 | 2017-11-07 | Yale University | Immunogenic epitopes as targets for universal cancer vaccines |
| EP3297660A2 (en) * | 2015-05-20 | 2018-03-28 | The Broad Institute Inc. | Shared neoantigens |
-
2018
- 2018-06-25 GB GBGB1810358.0A patent/GB201810358D0/en not_active Ceased
-
2019
- 2019-06-25 SG SG11202010976PA patent/SG11202010976PA/en unknown
- 2019-06-25 AU AU2019295371A patent/AU2019295371A1/en active Pending
- 2019-06-25 EP EP19736435.9A patent/EP3810175A1/en active Pending
- 2019-06-25 KR KR1020207033570A patent/KR20210023822A/ko unknown
- 2019-06-25 CA CA3099677A patent/CA3099677A1/en active Pending
- 2019-06-25 CN CN201980042288.XA patent/CN112292392A/zh active Pending
- 2019-06-25 MX MX2020013601A patent/MX2020013601A/es unknown
- 2019-06-25 EA EA202092861A patent/EA202092861A1/ru unknown
- 2019-06-25 JP JP2020572384A patent/JP2021529181A/ja active Pending
- 2019-06-25 WO PCT/GB2019/051785 patent/WO2020002899A1/en unknown
- 2019-06-25 BR BR112020023182-7A patent/BR112020023182A2/pt not_active IP Right Cessation
-
2020
- 2020-10-27 ZA ZA2020/06675A patent/ZA202006675B/en unknown
- 2020-12-11 US US17/119,899 patent/US12053513B2/en active Active
- 2020-12-21 IL IL279621A patent/IL279621A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021529181A (ja) | 2021-10-28 |
| IL279621A (en) | 2021-03-01 |
| ZA202006675B (en) | 2022-09-28 |
| WO2020002899A1 (en) | 2020-01-02 |
| US12053513B2 (en) | 2024-08-06 |
| SG11202010976PA (en) | 2021-01-28 |
| AU2019295371A1 (en) | 2020-12-17 |
| BR112020023182A2 (pt) | 2021-02-09 |
| EA202092861A1 (ru) | 2021-04-19 |
| US20210196807A1 (en) | 2021-07-01 |
| CA3099677A1 (en) | 2020-01-02 |
| KR20210023822A (ko) | 2021-03-04 |
| GB201810358D0 (en) | 2018-08-08 |
| CN112292392A (zh) | 2021-01-29 |
| EP3810175A1 (en) | 2021-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019005465A (es) | Metodo de tratamiento de un tumor inmunoterapeutico. | |
| MX2020005651A (es) | Receptor de antigeno quimerico dirigido a bcma y usos del mismo. | |
| MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MX2022010270A (es) | Nuevo enfoque para tratar el cancer mediante el uso de la inmunomodulacion. | |
| PH12017501934A1 (en) | Methods for treating or preventing migraine headache | |
| JO3735B1 (ar) | مركبات ألكين بها استبدال رباعي واستخداماتها | |
| SG10201811841UA (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| PH12016502354A1 (en) | Pharmaceutical composition | |
| MX2023014093A (es) | Compuestos que interactuan con glicano y metodos de uso. | |
| MX2019012884A (es) | Terapia de combinacion. | |
| MX2019007391A (es) | Sistema terapeutico transdermico que contiene asenapina. | |
| SG10201902664RA (en) | Combination therapy for treating cancer | |
| MX2020013601A (es) | Receptores de las celulas t especificos de cancer. | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| MX2021007453A (es) | Administracion perineural de resiniferatoxina para el tratamiento del dolor maladaptativo. | |
| EP3991749A3 (en) | A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody | |
| MY186134A (en) | Curcumin-peptide conjugates and formulations thereof | |
| MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
| NZ762312A (en) | Anti-pacap antibody | |
| MX2020001164A (es) | Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico. | |
| ZA202002107B (en) | Use of specific sirna against protein s for the treatment of hemophilia | |
| MX2019003751A (es) | Proteina terapeutica. | |
| PH12020500096A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor | |
| EA201792294A1 (ru) | Комбинированное лечение (варианты) с применением серибантумаба | |
| MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. |